AR108793A1 - Composiciones que comprenden timolol y un agente antiinflamatorio - Google Patents

Composiciones que comprenden timolol y un agente antiinflamatorio

Info

Publication number
AR108793A1
AR108793A1 ARP170101656A ARP170101656A AR108793A1 AR 108793 A1 AR108793 A1 AR 108793A1 AR P170101656 A ARP170101656 A AR P170101656A AR P170101656 A ARP170101656 A AR P170101656A AR 108793 A1 AR108793 A1 AR 108793A1
Authority
AR
Argentina
Prior art keywords
rosacea
treatment
timolol
topical
pharmaceutically acceptable
Prior art date
Application number
ARP170101656A
Other languages
English (en)
Inventor
Encuentra Gema Tarrason
Marina Nuria Godessart
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of AR108793A1 publication Critical patent/AR108793A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Refiere a combinaciones que comprenden timolol y un compuesto útil para el tratamiento de rosácea seleccionado de ivermectina, metronidazol y praziquantel y al uso de estas combinaciones en el tratamiento tópico de rosácea. Reivindicación 1: Combinación para su uso tópico que comprende (a) timolol o una sal farmacéuticamente aceptable del mismo, y (b) un compuesto activo útil para el tratamiento de rosácea seleccionado de ivermectina, metronidazol, praziquantel y sales farmacéuticamente aceptables de los mismos. Reivindicación 7: Composición farmacéutica adecuada para administración tópica que comprende una combinación según una cualquiera de las reivindicaciones 1 a 5, en la que los componentes (a) y (b) están presentes en la misma formulación. Reivindicación 9: Composición farmacéutica según una cualquiera de las reivindicaciones 7 u 8, en la que la composición es una loción, una crema o un gel. Reivindicación 14: Método de tratamiento de un paciente que padece rosácea, método que comprende administrar por vía tópica a dicho paciente una combinación según una cualquiera de las reivindicaciones 1 a 5 o una composición farmacéutica según una cualquiera de las reivindicaciones 7 a 10. Reivindicación 17: Uso de (a) timolol o una sal farmacéuticamente aceptable del mismo según una cualquiera de las reivindicaciones 1 ó 2 en la fabricación de un medicamento para el tratamiento de rosácea mediante coadministración tópica con (b) un agente antiinflamatorio según una cualquiera de las reivindicaciones 1, 3, 4 ó 5.
ARP170101656A 2016-06-16 2017-06-15 Composiciones que comprenden timolol y un agente antiinflamatorio AR108793A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16382279 2016-06-16

Publications (1)

Publication Number Publication Date
AR108793A1 true AR108793A1 (es) 2018-09-26

Family

ID=56148331

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101656A AR108793A1 (es) 2016-06-16 2017-06-15 Composiciones que comprenden timolol y un agente antiinflamatorio

Country Status (14)

Country Link
US (1) US20190231788A1 (es)
EP (1) EP3471719A1 (es)
JP (1) JP2019518045A (es)
KR (1) KR20190018440A (es)
CN (1) CN109475532A (es)
AR (1) AR108793A1 (es)
AU (1) AU2017285258A1 (es)
BR (1) BR112018075983A2 (es)
CA (1) CA3026625A1 (es)
EA (1) EA201990042A1 (es)
MA (1) MA45387A (es)
MX (1) MX2018015239A (es)
TW (1) TW201803569A (es)
WO (1) WO2017216309A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024134266A1 (en) * 2022-12-20 2024-06-27 Azura Ophthalmics Ltd. Compounds and methods for the treatment of dermal and ocular disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
FR2866567A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee
EP1979366A4 (en) * 2006-01-10 2011-05-25 Ruey J Yu N- (PHOSPHONOALKYL) -AMINOACES, DERIVATIVES AND COMPOSITIONS AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
EP3471719A1 (en) 2019-04-24
US20190231788A1 (en) 2019-08-01
MA45387A (fr) 2019-04-24
CN109475532A (zh) 2019-03-15
AU2017285258A1 (en) 2019-01-24
CA3026625A1 (en) 2017-12-21
MX2018015239A (es) 2019-04-15
TW201803569A (zh) 2018-02-01
KR20190018440A (ko) 2019-02-22
BR112018075983A2 (pt) 2019-04-02
JP2019518045A (ja) 2019-06-27
EA201990042A1 (ru) 2019-05-31
WO2017216309A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
AR065316A1 (es) Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales
NI201100154A (es) Métodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento, prevención y manejo de la tuberculosis
BR112022019914A2 (pt) Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CL2021001636A1 (es) Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
BR112019005578A2 (pt) compostos de indazol para uso em lesões no tendão e/ou ligamento
AR108793A1 (es) Composiciones que comprenden timolol y un agente antiinflamatorio
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial

Legal Events

Date Code Title Description
FB Suspension of granting procedure